her2基因在肺癌中的研究进展

doi:10.3969/j.issn.1674-490X.2010.04.030

摘要/Abstract

摘要： her2基因位于17q21,编码的蛋白质是具有酪氨酸蛋白激酶活性的跨膜蛋白,是人表皮生长因子受体之一.her2突变主要发生在外显子20.her2在肺癌中的表达可能与肺癌的类型、细胞分化程度及性别等存在一定的相关性.her2的单克隆抗体和小分子酪氨酸激酶抑制剂的临床试验虽然对her2异常的肺癌患者起到了一定作用,但并没有取得令人振奋的治疗效果.目前RNA干扰her2基因表达的试验正在进行,有望成为治疗肺癌的新策略.

关键词: her2, 肺癌, 单克隆抗体, 小分子酪氨酸激酶抑制剂, RNAi

中图分类号:

R734.2

李文艳,杨宏莉,杨静,耿坤静. her2基因在肺癌中的研究进展[J]. 医学研究与教育, 2010, 27(4): 83-86.

参考文献

[1] 张春雨, 李立. HER2/neu在正常肺组织及肺癌组织中的表达情况及其意义 [J]. 中国实验诊断学 2009.doi:10.3969/j.issn.1007-4287.2009.10.060
[2] 朱晓莉, 林勇, 唐剑英, 张祖贻, ZHU Xiao-li, LIN Yong, TANG Jian-ying, ZHANG Zu-yi. C-erb B-2基因在肺癌中表达意义的临床研究 [J]. 东南大学学报（医学版） 2006.doi:10.3969/j.issn.1671-6264.2006.01.012
[3] 刘汉勇, 王晓玫, 单军, 彭树松, 成志强, 彭全洲, CAI Jin-zhong, HU Jin-tao, LIU Han-yong, WANG Xiao-mei, SHAN Jun, PENG Shu-song, CHENG Zhi-qiang, PENG Quan-zhou, CAI Jin-zhong, HU Jin-tao. HER2和p300/CBP在非小细胞肺癌中表达及意义 [J]. 山东医药 2007.doi:10.3969/j.issn.1002-266X.2007.36.011
[4] 韩宇, 徐建明, 段海清, 张杨, 刘晓晴, 张京生, Yu Han, Jian-Ming Xu, Hai-Qing Duan, Yang Zhang, Xiao-Qing Liu, Jing-Sheng Zhang. EGFR基因突变及HER2/HER3蛋白表达水平与吉非替尼治疗晚期非小细胞肺癌疗效的关系 [J]. 癌症 2010.
[5] 虞伟, 张燕, 李晓军, 武建国, YU Wei, ZHANG Yan, LI Xiao-jun, WU Jian-guo. 抗-B淋巴细胞刺激因子自身抗体酶联免疫吸附法的建立和临床初步应用 [J]. 医学研究生学报 2007.doi:10.3969/j.issn.1008-8199.2007.10.003
[6] 申萍, 张方, 吴学玲, 施毅, 钱桂生, 罗向东, 胡波, 宋勇, SHEN Ping, ZHANG Fang, WU Xue-ling, SHI Yi, QIAN Gui-sheng, LUO Xiang-dong, HU Bo, SONG Yong. RNA干扰her2/neu基因表达抑制肺癌A549细胞增殖的研究 [J]. 医学研究生学报 2009.doi:10.3969/j.issn.1008-8199.2009.03.004
[7] Tiseo M, Loprevite M, Ardizzoni A. Epidermalgrowth factor receptor inhibitors:a new prospective in the treatment of lung cancer [J]. Current Medicinal Chemistry Anti-Cancer Agents 2004, 4(02).
[8] Wang SE, Narasanna A, Perez Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. [J]. Cancer Cell 2006, 1(1).
[9] Buttitta F, Barassi F, Fresu G. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients:mutations are mainly present in adenocarcinomas with bronchioloalveolar features [J]. International Journal of Cancer 2006, 119(11).
[10] Ugocsai K, Mandoky L, Tiszlavicz L, Molnar J. Investigation of HER2 overexpression in non-small cell lung cancer. [J]. Anticancer Research: International Journal of Cancer Research and Treatment 2005, 4(4).
[11] Cappuzzo F, Varella Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients. [J]. Journal of Clinical Oncology 2005, 22(22).
[12] Petit A M, Rak J, Hung M C. Neutraizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinase down-regulate vagcular endothelial growth factor production by tumor cells in vitro and invivo:angiogenic implication for signal transduction therapy of solid tumors [J]. American Journal of Pathology 1997, 151(06).
[13] Bunn P A, Helfrich B, Sariano A F. Expression of Her-2/neu in human lung cancer cell lines immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents [J]. Clinical Cancer Research 2001, 7(10).
[14] Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. [J]. Journal of Clinical Oncology 2004, 7(7).
[15] Scheuer W, Friess T, Burtscher. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. [J]. Cancer research 2009, 24(24).
[16] Hirata A, Hosoi F, Miyagawa M. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells [J]. Cancer Research 2005, 65(10).
[17] Soh J, Toyooka S, Ichihara S. Impact of HER2 and EGFR gene status on Gefitinib treated patients with nonsmall-cell lung cancer [J]. International Journal of Cancer 2007, 121(05).
[18] Hirsch F R, Varella-Garcia M, Cappuzzo F. Predictive value of EGFB and HEB2 overexpression in advanced non-small-cell lung cancer [J]. Oncogene 2009, 28(01).
[19] Ren XL, Xu YM, Bao W. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. [J]. Cancer letters 2009, 2(2).
[20] Ren XL, Xu YM, Bao W. [J]. Cancer letters 2009.